Video: AdAlta - executive interview
AdAlta is an Australian healthcare company focused on using its proprietary i-body discovery platform to target diseases, with an initial focus on conditions involving fibrosis. Its lead programme is AD-214 for the treatment of idiopathic pulmonary fibrosis, currently in Phase I. AdAlta has also licensed its platform to GE Healthcare for the purpose of diagnostic imaging. In this interview, CEO Tim Oldham provides an overview of the company’s programmes and reviews the recently announced clinical data for AD-214 as well as the company’s partnership strategy. See more at: https://www.edisongroup.com/edison-tv/
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
- Video: AdAlta - executive interview29 Mar 2021